Artelo Biosciences Inc (ARTL) Stock Price, Quote & News

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

NYSE_TRADERS Aug. 4 at 8:58 AM

$ARTL rad this again And open your eyes ! $ARTL 7 people in this scam company are spending 3 millions per quarter ( 12 millions per year ) to research cannabis opioid receptors … for 6 years ! They stole more than 60 millions so far over the last 6 years and still have morons who give them their hard earned money ! The world will finish , but stupidity win never finish on this world ! This garbage cost zero ! Beware

0 · Reply

GrinchyGainz Aug. 4 at 12:10 AM

$ARTL average $2.17. With news we fly again… and I’m outtt

1 · Reply

dglastone Aug. 3 at 4:48 PM

$ARTL very

3 · Reply

dglastone Aug. 3 at 3:33 PM

$ARTL total trash talker knows zero about this company only holding a big bad @ $100 pre splits.

0 · Reply

NYSE_TRADERS Aug. 3 at 2:11 PM

$ARTL read what negative equity value means !

1 · Reply

TurtleTeeTradez Aug. 3 at 2:07 PM

$ARTL One man’s trash is another man’s treasure.

0 · Reply

NYSE_TRADERS Aug. 3 at 2:05 PM

$ARTL 7 people in this scam company are spending 3 millions per quarter ( 12 millions per year ) to research cannabis opioid receptors … for 6 years ! They stole more than 60 millions so far over the last 6 years and still have morons who give them their hard earned money ! The world will finish , but stupidity win never finish on this world ! This garbage cost zero ! Beware

0 · Reply

ya33 Aug. 3 at 11:57 AM

$ARTL

0 · Reply

NYSE_TRADERS Aug. 3 at 8:42 AM

$ARTL This company is bankrupt ! What negative equity value of -1.27 millions means to you ? Question of days !!!! Delisting and Bankruptcy is coming next ! Nobody cares about your money ! Beware

0 · Reply

NYSE_TRADERS Aug. 3 at 8:29 AM

0 · Reply

Artelo Biosciences Transcript: AGM 2026

2026-07-16T12:55:39.000Z - 19 days ago

Artelo Biosciences announces new ART26.12 data

Jul 16, 2026, 8:48 AM EDT - 19 days ago

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Jul 16, 2026, 8:00 AM EDT - 19 days ago

Artelo Biosciences Proxy statement: Proxy filing

Jul 16, 2026, 8:00 AM EDT - 19 days ago

Artelo Biosciences Proxy statement: Proxy filing

Jul 14, 2026, 8:47 AM EDT - 21 days ago

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

2026-07-13T13:10:08.000Z - 22 days ago

Artelo Biosciences announces results from ART27.13 nonclinical studies

Jul 13, 2026, 9:02 AM EDT - 22 days ago

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Jul 2, 2026, 8:00 AM EDT - 4 weeks ago

Artelo Biosciences Proxy statement: Proxy filing

2026-07-01T13:40:23.000Z - 4 weeks ago

Artelo Biosciences presents preclinical pain data for ART26.12

Jul 1, 2026, 8:42 AM EDT - 4 weeks ago

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Jun 30, 2026, 8:57 AM EDT - 5 weeks ago

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

Jun 29, 2026, 8:45 AM EDT - 5 weeks ago

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Artelo Biosciences Proxy statement: Proxy filing

Jun 10, 2026, 7:38 AM EDT - 7 weeks ago

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 7:00 AM EDT - 2 months ago

Artelo Biosciences Slides: Corporate presentation

May 26, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Proxy statement: Proxy filing

May 20, 2026, 7:00 AM EDT - 2 months ago

Artelo Biosciences Slides: Corporate presentation

May 14, 2026, 4:05 PM EDT - 2 months ago

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

May 14, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Registration statement: Registration filing

May 14, 2026, 7:00 AM EDT - 2 months ago

Artelo Biosciences Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Artelo Biosciences Earnings release: Q1 2026

2026-05-04T20:48:41.000Z - 3 months ago

Artelo Biosciences files $75M mixed securities shelf

May 4, 2026, 8:00 AM EDT - 3 months ago

Artelo Biosciences Registration statement: Registration filing

2026-04-28T13:43:29.000Z - 3 months ago

Artelo Biosciences announces collaboration with ScienceMachine

Apr 28, 2026, 8:25 AM EDT - 3 months ago

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

2026-04-20T12:15:49.000Z - 3 months ago

Artelo Biosciences announces publication of article on ART26.12

Apr 20, 2026, 7:50 AM EDT - 3 months ago

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Apr 15, 2026, 7:00 AM EDT - 3 months ago

Artelo Biosciences Slides: Corporate presentation

2026-04-07T20:25:22.000Z - 4 months ago

Artelo Biosciences files to sell 9.82M shares of common stock for holders

2026-04-07T13:09:13.000Z - 4 months ago

Artelo Biosciences regains compliance with Nasdaq

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Apr 7, 2026, 7:50 AM EDT - 4 months ago

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Mar 30, 2026, 4:46 PM EDT - 4 months ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

2026-03-30T09:39:29.000Z - 4 months ago

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

LLY NVO

2026-03-27T14:45:29.000Z - 4 months ago

Artelo Biosciences announces $11M private placement priced at-the-market

Mar 27, 2026, 10:40 AM EDT - 4 months ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

2026-03-25T20:40:32.000Z - 4 months ago

Artelo announces expansion opportunity for ART27.13 in muscle preservation

Mar 25, 2026, 4:05 PM EDT - 4 months ago

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Mar 25, 2026, 7:31 AM EDT - 4 months ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

2026-03-24T21:35:16.000Z - 4 months ago

Artelo Biosciences files to sell 4.27M shares of common stock for holders

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Artelo Biosciences Slides: Corporate presentation

2026-03-20T21:20:34.000Z - 4 months ago

Artelo Biosciences files to sell 1.64M shares of common stock

Mar 20, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 18, 2026, 10:41 AM EDT - 4 months ago

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

YYGH

Mar 18, 2026, 8:07 AM EDT - 4 months ago

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

2026-03-18T11:45:26.000Z - 4 months ago

Artelo announces third-party fully funded clinical study agreement for ART27.13

Mar 18, 2026, 7:41 AM EDT - 4 months ago

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

2026-03-09T23:50:10.000Z - 5 months ago

Artelo Biosciences Inc trading halted, news pending

2026-03-06T13:13:39.000Z - 5 months ago

Artelo Biosciences announces 3-for-1 reverse stock split

Mar 6, 2026, 8:00 AM EST - 5 months ago

Artelo Biosciences Announces Reverse Stock Split

2026-02-24T13:05:52.000Z - 5 months ago

Artelo Biosciences reports FY25 EPS ($12.52)

Feb 24, 2026, 8:00 AM EST - 5 months ago

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Feb 24, 2026, 7:00 AM EST - 5 months ago

Artelo Biosciences Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 5 months ago

Artelo Biosciences Annual report: Q4 2025

Jan 30, 2026, 11:00 AM EST - 6 months ago

Artelo Biosciences Transcript: AGM 2026

Jan 8, 2026, 7:00 AM EST - 7 months ago

Artelo Biosciences Slides: Investor presentation

Jan 7, 2026, 7:00 AM EST - 7 months ago

Artelo Biosciences Proxy statement: Proxy Filing

Dec 23, 2025, 9:00 AM EST - 8 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Dec 11, 2025, 7:00 AM EST - 8 months ago

Artelo Biosciences Proxy statement: Proxy filing

Nov 17, 2025, 7:00 AM EST - 9 months ago

Artelo Biosciences Registration statement: Registration Filing

Nov 12, 2025, 4:00 PM EST - 9 months ago

Artelo Biosciences Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

Artelo Biosciences Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 9 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 15, 2025, 9:15 AM EDT - 10 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 1, 2025, 4:05 PM EDT - 10 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025, 7:15 PM EDT - 11 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 8:30 AM EDT - 11 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 5, 2025, 4:05 PM EDT - 11 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 11 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 3, 2025, 11:33 AM EDT - 11 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 8:45 AM EDT - 11 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 1 year ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Artelo Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Artelo Biosciences Quarterly report: Q2 2025

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Proxy statement: Proxy Filing

Aug 4, 2025, 7:30 AM EDT - 1 year ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Proxy statement: Proxy Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Registration statement: Registration Filing

Jul 9, 2025, 7:50 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 7, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 1 year ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Mar 2, 2025, 6:00 PM EST - 1 year ago

Artelo Biosciences Earnings release: Q4 2024

Mar 2, 2025, 6:00 PM EST - 1 year ago

Artelo Biosciences Annual report: Q4 2024

Feb 14, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 11, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

NYSE_TRADERS Aug. 4 at 8:58 AM

0 · Reply

GrinchyGainz Aug. 4 at 12:10 AM

$ARTL average $2.17. With news we fly again… and I’m outtt

1 · Reply

dglastone Aug. 3 at 4:48 PM

$ARTL very

3 · Reply

dglastone Aug. 3 at 3:33 PM

$ARTL total trash talker knows zero about this company only holding a big bad @ $100 pre splits.

0 · Reply

NYSE_TRADERS Aug. 3 at 2:11 PM

$ARTL read what negative equity value means !

1 · Reply

TurtleTeeTradez Aug. 3 at 2:07 PM

$ARTL One man’s trash is another man’s treasure.

0 · Reply

NYSE_TRADERS Aug. 3 at 2:05 PM

0 · Reply

ya33 Aug. 3 at 11:57 AM

$ARTL

0 · Reply

NYSE_TRADERS Aug. 3 at 8:42 AM

$ARTL This company is bankrupt ! What negative equity value of -1.27 millions means to you ? Question of days !!!! Delisting and Bankruptcy is coming next ! Nobody cares about your money ! Beware

0 · Reply

NYSE_TRADERS Aug. 3 at 8:29 AM

0 · Reply

Azahmad Jul. 31 at 10:30 PM

$ARTL Any good news and this go’s. Could go nuts.

0 · Reply

TurtleTeeTradez Jul. 31 at 4:43 PM

$ARTL https://x.com/turtleteetradez/status/2083223304790556866?s=46&t=8sABjKlJtb_nHLTzfWajPw

0 · Reply

dglastone Jul. 31 at 4:34 PM

$ARTL this micro cap bio tech is a perfect buyout target.

1 · Reply

Adubstradesmini Jul. 31 at 1:42 PM

$ARTL moving on low volume

1 · Reply

Adubstradesmini Jul. 31 at 11:58 AM

$SLV $ARTL

0 · Reply

TurtleTeeTradez Jul. 31 at 1:17 AM

$ARTL $0.8 close AH 💪💪💪

0 · Reply

TurtleTeeTradez Jul. 30 at 10:00 PM

$ARTL Somebody is pushing it up AH!

0 · Reply

dglastone Jul. 30 at 5:50 PM

$ARTL looking like it'll close above .80 today. Got my price i've been waiting for at .75 so im good, time will tell. Looks like all the weak hands are out for now.

1 · Reply

dglastone Jul. 30 at 5:12 PM

$ARTL i bet the MM's where shorting the crap out of this through dark pools.

0 · Reply

TurtleTeeTradez Jul. 30 at 4:44 PM

$ARTL way overdue for a big run here! I expect a massive pump within the next few days.

2 · Reply

dglastone Jul. 30 at 3:36 PM

$ARTL looks like capitulation may have been yesterday

0 · Reply

TurtleTeeTradez Jul. 30 at 2:08 PM

$ARTL Added yesterday and this morning! This has to run at some point!

0 · Reply

Market Cap	1.80M
Revenue (ttm)	0.00
Net Income (ttm)	-12.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	128,200
Avg Vol	1,194,544
Day's Range	N/A - N/A
Shares Out	2.33M
Stochastic %K	9%
Beta	-0.11
Analysts	Hold
Price Target	$18.00